Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Roche
Pharma
Roche touts near-complete MS suppression for injectable Ocrevus
Roche's subcutaneous Ocrevus helped 97% of multiple sclerosis patients achieve no relapse up to 48 weeks of treatment.
Angus Liu
Apr 17, 2024 11:00am
Roche eyes earlier treatment nod after Columvi-chemo trial win
Apr 15, 2024 11:36am
Top 20 pharma companies by 2023 revenue
Apr 15, 2024 3:00am
Enspryng falls short of Roche's expectations in myasthenia gravis
Mar 21, 2024 11:28am
Lonza strikes $1.2B deal to buy mammoth Roche plant
Mar 20, 2024 11:33am
As Imbruvica fails, Brukinsa wins FDA nod in follicular lymphoma
Mar 7, 2024 4:08pm